| Camilo Rubio-uribe, CRNA | |
|
565 Coal Valley Rd, Jefferson Hills, PA 15025-3703 | |
| (412) 469-5000 | |
| (412) 469-7174 |
| Full Name | Camilo Rubio-uribe |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 11 Years |
| Location | 565 Coal Valley Rd, Jefferson Hills, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508290750 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | RN600620 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Jefferson Hospital | Jefferson hills, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Allegheny Clinic | 5395649586 | 1941 |
News Archive
Final first-in-man (FIM) clinical results on the use of the FlexStent® Femoropopliteal SE Stent System were presented recently at the VIVA conference in Las Vegas by Dr. Andrew Holden of Auckland City Hospital. The clinical results originated from Flexible Stenting Solutions, Inc.'s (FSS) FIM study conducted in New Zealand by Principle Investigator Dr. Andrew Holden, and FSS's supplementary study conducted in Germany by Principle Investigator Dr. Dierk Scheinert of University of Leipzig - Heart Center.
One or two rounds of high coverage mass treatment with azithromycin, rather than the annual treatment recommended by the World Health Organisation, may be enough to eliminate the eye disease trachoma in communities with moderate levels of infection.
While the number of people - especially women - who have a minimally invasive procedure to remove kidney stones has risen in recent years, so has the rate of complications related to the surgery, according to a published study by Henry Ford Hospital in Detroit.
Schering AG, Germany announced today that, following regulatory approvals, it will co-promote the novel oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK) for all oncology indications together with Novartis Pharma AG in Europe, North America and Japan. This agreement will enable both Schering and Novartis to maximize the compound's full potential.
› Verified 1 days ago
| Entity Name | Anesthesia Consultants Of Erie Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003809559 PECOS PAC ID: 9830092626 Enrollment ID: O20040129000458 |
News Archive
Final first-in-man (FIM) clinical results on the use of the FlexStent® Femoropopliteal SE Stent System were presented recently at the VIVA conference in Las Vegas by Dr. Andrew Holden of Auckland City Hospital. The clinical results originated from Flexible Stenting Solutions, Inc.'s (FSS) FIM study conducted in New Zealand by Principle Investigator Dr. Andrew Holden, and FSS's supplementary study conducted in Germany by Principle Investigator Dr. Dierk Scheinert of University of Leipzig - Heart Center.
One or two rounds of high coverage mass treatment with azithromycin, rather than the annual treatment recommended by the World Health Organisation, may be enough to eliminate the eye disease trachoma in communities with moderate levels of infection.
While the number of people - especially women - who have a minimally invasive procedure to remove kidney stones has risen in recent years, so has the rate of complications related to the surgery, according to a published study by Henry Ford Hospital in Detroit.
Schering AG, Germany announced today that, following regulatory approvals, it will co-promote the novel oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK) for all oncology indications together with Novartis Pharma AG in Europe, North America and Japan. This agreement will enable both Schering and Novartis to maximize the compound's full potential.
› Verified 1 days ago
| Entity Name | Allegheny Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073081493 PECOS PAC ID: 5395649586 Enrollment ID: O20040310000602 |
News Archive
Final first-in-man (FIM) clinical results on the use of the FlexStent® Femoropopliteal SE Stent System were presented recently at the VIVA conference in Las Vegas by Dr. Andrew Holden of Auckland City Hospital. The clinical results originated from Flexible Stenting Solutions, Inc.'s (FSS) FIM study conducted in New Zealand by Principle Investigator Dr. Andrew Holden, and FSS's supplementary study conducted in Germany by Principle Investigator Dr. Dierk Scheinert of University of Leipzig - Heart Center.
One or two rounds of high coverage mass treatment with azithromycin, rather than the annual treatment recommended by the World Health Organisation, may be enough to eliminate the eye disease trachoma in communities with moderate levels of infection.
While the number of people - especially women - who have a minimally invasive procedure to remove kidney stones has risen in recent years, so has the rate of complications related to the surgery, according to a published study by Henry Ford Hospital in Detroit.
Schering AG, Germany announced today that, following regulatory approvals, it will co-promote the novel oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK) for all oncology indications together with Novartis Pharma AG in Europe, North America and Japan. This agreement will enable both Schering and Novartis to maximize the compound's full potential.
› Verified 1 days ago
| Entity Name | St Clair Anesthesiology Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154380384 PECOS PAC ID: 5294627345 Enrollment ID: O20040325000797 |
News Archive
Final first-in-man (FIM) clinical results on the use of the FlexStent® Femoropopliteal SE Stent System were presented recently at the VIVA conference in Las Vegas by Dr. Andrew Holden of Auckland City Hospital. The clinical results originated from Flexible Stenting Solutions, Inc.'s (FSS) FIM study conducted in New Zealand by Principle Investigator Dr. Andrew Holden, and FSS's supplementary study conducted in Germany by Principle Investigator Dr. Dierk Scheinert of University of Leipzig - Heart Center.
One or two rounds of high coverage mass treatment with azithromycin, rather than the annual treatment recommended by the World Health Organisation, may be enough to eliminate the eye disease trachoma in communities with moderate levels of infection.
While the number of people - especially women - who have a minimally invasive procedure to remove kidney stones has risen in recent years, so has the rate of complications related to the surgery, according to a published study by Henry Ford Hospital in Detroit.
Schering AG, Germany announced today that, following regulatory approvals, it will co-promote the novel oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK) for all oncology indications together with Novartis Pharma AG in Europe, North America and Japan. This agreement will enable both Schering and Novartis to maximize the compound's full potential.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Camilo Rubio-uribe, CRNA 565 Coal Valley Rd, Jefferson Hills, PA 15025-3703 Ph: (412) 469-5000 | Camilo Rubio-uribe, CRNA 565 Coal Valley Rd, Jefferson Hills, PA 15025-3703 Ph: (412) 469-5000 |
News Archive
Final first-in-man (FIM) clinical results on the use of the FlexStent® Femoropopliteal SE Stent System were presented recently at the VIVA conference in Las Vegas by Dr. Andrew Holden of Auckland City Hospital. The clinical results originated from Flexible Stenting Solutions, Inc.'s (FSS) FIM study conducted in New Zealand by Principle Investigator Dr. Andrew Holden, and FSS's supplementary study conducted in Germany by Principle Investigator Dr. Dierk Scheinert of University of Leipzig - Heart Center.
One or two rounds of high coverage mass treatment with azithromycin, rather than the annual treatment recommended by the World Health Organisation, may be enough to eliminate the eye disease trachoma in communities with moderate levels of infection.
While the number of people - especially women - who have a minimally invasive procedure to remove kidney stones has risen in recent years, so has the rate of complications related to the surgery, according to a published study by Henry Ford Hospital in Detroit.
Schering AG, Germany announced today that, following regulatory approvals, it will co-promote the novel oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK) for all oncology indications together with Novartis Pharma AG in Europe, North America and Japan. This agreement will enable both Schering and Novartis to maximize the compound's full potential.
› Verified 1 days ago
Mrs. Victoria L Riley, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 565 Coal Valley Rd, Jefferson Hills, PA 15025 Phone: 412-469-5000 Fax: 412-469-7174 | |
Adam A Barone, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 565 Coal Valley Rd, Jefferson Hills, PA 15025 Phone: 412-469-5000 Fax: 412-469-7174 | |
Ms. Nicole Marie De Gortari, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 565 Coal Valley Rd, Jefferson Hills, PA 15025 Phone: 412-469-5000 Fax: 412-469-7174 | |
Jennifer Vlahos, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 565 Coal Valley Rd, Jefferson Hills, PA 15025 Phone: 412-469-5000 | |
Kerrie Reffert, RN Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 565 Coal Valley Rd, Jefferson Hills, PA 15025 Phone: 412-469-5000 Fax: 412-469-7174 | |
Sarah E Griener, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 565 Coal Valley Rd, Jefferson Hills, PA 15025 Phone: 412-469-5000 Fax: 412-469-7174 | |
Ashley Rae Wehner, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 565 Coal Valley Rd, Jefferson Hills, PA 15025 Phone: 412-469-5000 |